Features Screener Stocks Charts
Sign In Sign Up

Neuland Laboratories Limited Cash Flow Statement

NSE:NEULANDLAB | PHARMACEUTICALS

Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.

View Plans

Cash Flow Insights

Cash Conversion

0.92x

NEULANDLAB's operating cash flow covered 92% of net income in FY 2025. Some earnings may be tied up in working capital.

Free Cash Flow

₹1.11B

NEULANDLAB's free cash flow was ₹1.11B in FY 2025, down 5.6% from FY 2024.

Dividend Coverage

6.2x

NEULANDLAB's free cash flow covered dividends 6.2x in FY 2025, leaving room for reinvestment or debt reduction.

CapEx Intensity

65.1%

Capital expenditure consumed 65.1% of operating cash flow in FY 2025 for NEULANDLAB, typical of capital-intensive industries.

2-year NEULANDLAB cash flow snapshot

Hover the chart icon for YoY change.

FY 2024 - FY 2025
Item Chart 2024 2025
Net Income 4.01B 3.46B
Cash flow Operating Activities 2.61B 3.17B
Investments in PPE -1.44B -2.06B
Cash flow Investing Activities -1.50B -2.98B
Dividend Paid -128.30M -179.62M
Cash flow Financing Activities -692.82M 249.61M
Cash at beginning of period 454.16M 875.75M
Cash at end of period 875.75M 1.32B
Free Cash Flow 1.18B 1.11B

Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025